Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and genetic and metabolic diseases in Europe, North America, and internationally. It offers Alprolix for haemophilia B; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection. The company It also provides other products, such as Akynzeo, Aloxi, Ammonul, Betapred, Caphosol, Fibclot, IVheBex, and Willfact. In addition, it develops drug substance for ReFacto AF/Xyntha for Pfizer; BIVV001 for haemophilia A; and Nirsevimab for respiratory syncytial virus. The company has a strategic collaboration with Apellis Pharmaceuticals Inc. to develop pegcetacoplan for the treatment of multiple rare diseases, including paroxysmal nocturnal hemoglobinuria. Swedish Orphan Biovitrum AB (publ) is headquartered in Solna, Sweden.

Insider	Title	Transaction Type	Shares Traded	% of Shares Traded	% Chg. in Shares	End of Filing Shares	Price	Transaction Value	Filing Date	Transaction Date
Guido Oelkers	CEO & President, Group Chief Executive, Director Show All	Open Market Acquisition (Buy)	70K	0.020436%	19.6%	427.11K	SEK 14.24 - SEK 14.24	SEK 996.87K	30 Aug 2024	30 Aug 2024 - 30 Aug 2024
Guido Oelkers	CEO & President, Group Chief Executive, Director Show All	Open Market Disposition (Sale)	-70K	-0.020436%	-14.08%	427.11K	SEK 30.71 - SEK 30.77	-SEK 2.15M	30 Aug 2024	28 Aug 2024 - 28 Aug 2024
Torbjörn Hallberg	General Counsel & Head of Legal Affairs, Director Show All	Open Market Acquisition (Buy)	84.53K	0.024677%	-156.47%	30.51K	SEK 14.24 - SEK 14.24	SEK 1.2M	30 Aug 2024	30 Aug 2024 - 30 Aug 2024
Torbjörn Hallberg	General Counsel & Head of Legal Affairs, Director Show All	Open Market Disposition (Sale)	-84.53K	-0.024677%	-73.48%	30.51K	SEK 31.31 - SEK 31.31	-SEK 2.65M	30 Aug 2024	28 Aug 2024 - 28 Aug 2024
Henrik Stenqvist	Chief Financial Officer, Independent Director, Independent Non-Executive Director, Director Show All	Other Acquisition (Buy)	96.11K	0.028059%	-241.7%	56.35K	SEK 14.26 - SEK 14.26	SEK 1.37M	29 Aug 2024	29 Aug 2024 - 29 Aug 2024
Henrik Stenqvist
Guido Oelkers
Guido Oelkers
Armin Reininger
Daniel Rankin
Daniel Rankin
Katy Mazibuko
Guido Oelkers
Mahmood Ladha
Mahmood Ladha
Christine Wesstrom
Christine Wesstrom
Guido Oelkers
Guido Oelkers
Mahmood Ladha
Mahmood Ladha
Armin Reininger
Armin Reininger
Armin Reininger
Duane H. Barnes
Duane H. Barnes
Guido Oelkers
Guido Oelkers
Guido Oelkers
Guido Oelkers